Moran Timothy P. sold $94K of KMTS

Moran Timothy P. (Chief Business Officer) sold 3,192 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $29.56 on 2026-11-03.

Original reporting
SEC EDGAR · Moran Timothy P.
Published Nov 5, 2026, 10:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

A modest insider sale, unlikely to move the stock significantly but may attract short‑term traders.

02

Market read

Primary disclosure of a small insider sale; low trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: post‑market 2026‑11‑05

Background

SEC Form 4 filing provides the first public disclosure of the insider transaction.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 disclosed Chief Business Officer sold 3,192 shares for $94,352, a new insider sale.

Expected impact

likely slight downward pressure as the market prices the sale.

Evidence & confidence

Sale size is small relative to holdings and market cap, but insider sales often trigger short-term selling.

Market effects

Minimal impact on the medical device sector; no broader trend indicated.

Limited to U.S. investors tracking insider activity.

None

Counterpoint

The sale could be routine liquidity management and not a negative signal.

Key entities

  • KestrA Medical Technologies, Ltd.

    Medical device manufacturer listed on Nasdaq under KMTS.

  • Moran Timothy P.

    Chief Business Officer of KMTS, reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.